T-Cell Engagers in Solid Cancers—Current Landscape and Future Directions

ABSTRACT:

Simple Summary

There are multiple strategies to target cancer cells, and among the rapidly evolving field is the use of bispecific antibodies and T-cell engagers in the treatment of cancers. These drugs work by recruiting and activating T-cells, a type of white blood cell, to recognize and attack cancer cells. These agents consist of two different antibody fragments: one that binds to a tumor antigen on cancer cells and another that binds to the CD3 receptor on T-cells. Once the T-cell engager binds to both the cancer cell and T-cell, it brings the T-cell into close proximity to the cancer cell, leading to the activation of T-cells and the release of cytokines and cytotoxic molecules that kill the cancer cell. T-cell engagers have shown promising results in the treatment of a vari

SUBMITTER: Shanshal M 

PROVIDER: S-EPMC10216491 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature